Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On Aug.</li><li>7, 2026, Atossa Therapeutics, Inc. (ATOS) announced financial results for the second quarter of 2026 and provided a business update.</li><li>The company is approaching a potentially transformative period as two Phase 2 studies of (Z)-endoxifen are expected to produce data by year-end.</li></ul>

On Aug.7, 2026, Atossa Therapeutics, Inc. (ATOS) announced financial results for the second quarter of 2026 and provided a business update.The company is approaching a potentially transformative period as two Phase 2 studies of (Z)-endoxifen are expected to produce data by year-end.

ATOS: Multiple Catalysts Converge in 2H26